All In Biotech

Drug Trial Radar · NCT07619131

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.

Conditions

  • Hypercholesterolaemia

Interventions

  • LaroprovstatDrug

    daily oral dose of the Laroprovstat

  • Rosuvastatin 1Drug

    daily oral dose of the Rosuvastatin 1

  • Rosuvastatin 2Drug

    daily oral dose of the Rosuvastatin 2

  • Laroprovstat/Rosuvastatin 1Drug

    daily oral dose of the Laroprovstat/Rosuvastatin 1

  • Placebo to match rosuvastatinDrug

    daily oral dose of the Placebo to match Rosuvastatin

  • Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1Drug

    daily oral dose of the Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1

  • Laroprovstat/Rosuvastatin 2Drug

    daily oral dose of the Laroprovstat/Rosuvastatin 2

  • Placebo to match Laroprovstat/Rosuvastatin 2Drug

    daily oral dose of the Placebo to match Laroprovstat/Rosuvastatin 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in LDL-C at 8 weeksTime frame: 8 weeks
  2. Relative change in LDL-C at 8 weeksTime frame: 8 weeks

Locations

152 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama · Not yet recruiting

  • Research Site

    Chandler, Arizona · Not yet recruiting

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Huntington Beach, California · Not yet recruiting

  • Research Site

    Loma Linda, California · Not yet recruiting

  • Research Site

    Lomita, California · Not yet recruiting

  • Research Site

    Long Beach, California · Not yet recruiting

  • Research Site

    San Dimas, California · Not yet recruiting

  • Research Site

    Arvada, Colorado · Not yet recruiting

  • Research Site

    Colorado Springs, Colorado · Recruiting

  • Research Site

    Waterbury, Connecticut · Not yet recruiting

  • Research Site

    Clearwater, Florida · Not yet recruiting

  • Research Site

    DeLand, Florida · Not yet recruiting

  • Research Site

    Hollywood, Florida · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Lakeland, Florida · Recruiting

  • Research Site

    Miami Lakes, Florida · Not yet recruiting

  • Research Site

    Ocoee, Florida · Not yet recruiting

  • Research Site

    Plantation, Florida · Not yet recruiting

  • Research Site

    Port Orange, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Conyers, Georgia · Recruiting

  • Research Site

    Decatur, Georgia · Not yet recruiting

  • Research Site

    Hinesville, Georgia · Recruiting

  • Research Site

    Peachtree Corners, Georgia · Not yet recruiting

  • Research Site

    Champaign, Illinois · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Island Lake, Illinois · Not yet recruiting

  • Research Site

    Melrose Park, Illinois · Not yet recruiting

  • Research Site

    Palos Hills, Illinois · Not yet recruiting

  • Research Site

    Evansville, Indiana · Not yet recruiting

  • Research Site

    Waterloo, Iowa · Not yet recruiting

  • Research Site

    Derby, Kansas · Not yet recruiting

  • Research Site

    Lexington, Kentucky · Recruiting

  • Research Site

    Louisville, Kentucky · Not yet recruiting

  • Research Site

    Zachary, Louisiana · Not yet recruiting

  • Research Site

    Annapolis, Maryland · Not yet recruiting

  • Research Site

    Beltsville, Maryland · Not yet recruiting

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.